The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.
This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's. This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.
|· Describe the important features of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) with commonly employed non-pharmacologic and pharmacologic treatments|
|· Identify the pharmacologic features of MDMA and psilocybin and clinical trial results when applied to patients with mental health disorders|
|· Describe legal barriers to using psychedelics in patients with mental health disorders and ways to circumvent them at a national or state level|
Released: April 28, 2022
Expires: April 28, 2025
ACPE UAN Codes
1.0 hours of CE
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour for completing the activity (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
C. Michael White, PharmD, FCCP, FCP
Professor and Department Head Pharmacy Practice
University of Connecticut School of Pharmacy and Director HOPES Research Group
Dr. White has no financial relationships with any ineligible company associated with these presentations.
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.